Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07349381). This is a study registration, not published results. Lead sponsor: Vincentage Pharma Co., Ltd. Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 32 participants (ACTUAL). Conditions: Obesity & Overweight, Type 2 Diabetes. Interventions: DRUG: CX11 (VCT220). Primary outcome measures: Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of CX11 (VCT220) , Predose at Day1 up to 35 days postdose; Maximum Observed Concentration (Cmax) of CX11 (VCT220) , Predose at Day1 up to 35 days postdose; Time to Maximum Observed Concentration (Tmax) of CX11 (VCT220) , Predose at Day 1 up to 35 days postdose. Brief summary: This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants